Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Novartis acellular pertussis vaccine
- Development stage
- Unknown
- Lead developer
- Novartis
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The Novartis acellular pertussis vaccine is an investigational protein subunit vaccine designed to prevent pertussis (whooping cough) caused by *Bordetella pertussis*. It is composed of three purified antigens: genetically detoxified pertussis toxin (PT), filamentous hemagglutinin (FHA), and pertactin (PRN). Unlike traditional acellular pertussis vaccines that use chemical detoxification (e.g., with formaldehyde), this vaccine utilizes a genetically modified version of the pertussis toxin that is inherently non-toxic while maintaining superior structural integrity and immunogenicity. Developed by Novartis Vaccines and Diagnostics, the vaccine has been evaluated in Phase 1 clinical trials (such as study V113_01) as both a standalone booster (aP) and as part of a combination tetanus-diphtheria-acellular pertussis (TdaP) booster in healthy adults.
- Other names
- Novartis aP vaccineNovartis TdaP vaccinegenetically detoxified pertussis vaccine
02
Targets
FHA (Filamentous hemagglutinin)PRN (Pertactin)
Beyond the preview
Go deeper on Novartis acellular pertussis vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Novartis acellular pertussis vaccine.